News by Subject Medicine & Health

State crisis standards of care (CSC) guidelines in the U.S. allocate scarce health care resources among patients, and this study examined the implications of these guidelines for patients with cancer, including allocation methods, cancer-related categorical exclusions and deprioritizations, and provisions for blood products and palliative care.

Octapharma USA will present multiple clinical research posters focused on the efficacy and safety of fibryga®, Fibrinogen (Human) Lyophilized Powder for Reconstitution, for Intravenous Use in the treatment of congenital and acquired bleeding disorders during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, a virtual medical congress to be held December 5 - 8, 2020.

Metabolites are small molecules found in our body's cells. They come from the food we eat, chemical processes happening within our bodies and microbes. A new analysis of recent studies has found that the levels of 10 metabolites detected in the blood are associated with a person's risk of stroke. The research is published in the December 2, 2020, online issue of Neurology®, the medical journal of the American Academy of Neurology.

Clinical research presented by Octapharma USA at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition will highlight the investigational use of high-dose Octagam® 10% [Immune Globulin Intravenous (Human)] for the most severe COVID-19 patients. Octapharma's intravenous immunoglobulin (IVIg) portfolio also will be featured in a study design poster focused on primary infection prophylaxis in patients with chronic lymphocytic leukemia during ASH, to be held virtually December 5 - 8 due to the coronavirus pandemic.

Octapharma USA will present its most recent rare bleeding disorders research initiatives during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, a virtual medical congress to be held December 5 - 8.

Men who have the Western world's most common genetic disorder, haemochromatosis, are ten times more likely to develop liver cancer, according to a major new study.